Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 439

1.

Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplantation in multiple myeloma.

Rosiñol L, Oriol A, Rios R, Sureda A, Blanchard MJ, Hernández MT, Martínez-Martínez R, Moraleda JM, Jarque I, Bargay J, Gironella M, de Arriba F, Palomera L, Gonzalez-Montes Y, Marti J, Krsnik I, Arguiñano JM, Gonzalez ME, Gonzalez AP, Casado LF, Lopez-Anglada L, Paiva B, Mateos MV, San Miguel J, Lahuerta JJ, Bladé J.

Blood. 2019 Sep 4. pii: blood.2019000241. doi: 10.1182/blood.2019000241. [Epub ahead of print]

PMID:
31484647
2.

CAR-T cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network.

Moreau P, Sonneveld P, Boccadoro M, Cook G, Mateos MV, Nahi H, Goldschmidt H, Dimopoulos MA, Lucio P, Bladé J, Delforge M, Hajek R, Ludwig H, Facon T, San Miguel JF, Einsele H.

Haematologica. 2019 Aug 22. pii: haematol.2019.224204. doi: 10.3324/haematol.2019.224204. [Epub ahead of print]

3.

Six-2 glomerular expression for the prediction of renal outcome in systemic amyloidosis.

Rodas LM, Garcia-Herrera A, Ramirez Bajo M, Fernandez-Larrea C, Cibeira MT, Blasco M, Rosiñol L, Solé M, Blade J, Campistol JM, Quintana LF.

Amyloid. 2019;26(sup1):97-98. doi: 10.1080/13506129.2019.1582483. No abstract available.

PMID:
31343337
4.

A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome.

Beksac M, Cengiz Seval G, Kanellias N, Coriu D, Rosiñol L, Ozet G, Goranova-Marinova V, Unal A, Bila J, Ozsan H, Ivanaj A, Balić LI, Kastritis E, Bladé J, Dimopoulos MA.

Haematologica. 2019 Jul 5. pii: haematol.2019.219295. doi: 10.3324/haematol.2019.219295. [Epub ahead of print]

5.

Late Onset Graft Plasmacytoma-Like PTLD Presenting as Acute Hyperglycemia in a Kidney-Pancreas Transplant Recipient.

Ventura-Aguiar P, Cibeira MT, Martinez A, Cuatrecasas M, Aymerich M, Ferrer J, Blade J, Diekmann F, Ricart MJ.

Case Rep Nephrol. 2019 May 19;2019:2818074. doi: 10.1155/2019/2818074. eCollection 2019.

6.

Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma.

Chari A, Martinez-Lopez J, Mateos MV, Bladé J, Benboubker L, Oriol A, Arnulf B, Rodriguez-Otero P, Pineiro L, Jakubowiak A, de Boer C, Wang J, Clemens PL, Ukropec J, Schecter J, Lonial S, Moreau P.

Blood. 2019 Aug 1;134(5):421-431. doi: 10.1182/blood.2019000722. Epub 2019 May 21.

PMID:
31113777
7.

Role of urine immunofixation in the complete response assessment of MM patients other than light-chain-only disease.

Lahuerta JJ, Jiménez-Ubieto A, Paiva B, Martínez-López J, González-Medina J, López-Anglada L, Cedena MT, Puig N, Oriol A, Blanchard MJ, Ríos R, Martin J, Martínez R, Sureda A, Hernández MT, de la Rubia J, Krsnik I, Cabañas V, Palomera L, Bargay J, Mateos MV, Rosiñol L, San Miguel JF, Blade J.

Blood. 2019 Jun 20;133(25):2664-2668. doi: 10.1182/blood.2019000671. Epub 2019 Apr 22.

PMID:
31010846
8.

Predicting long-term disease control in transplant-ineligible patients with multiple myeloma: impact of an MGUS-like signature.

Rodríguez-Otero P, Mateos MV, Martínez-López J, Hernández MT, Ocio EM, Rosiñol L, Martínez R, Teruel AI, Gutiérrez NC, Bargay J, Bengoechea E, González Y, de Oteyza JP, Gironella M, Nuñez-Córdoba JM, Encinas C, Martín J, Cabrera C, Palomera L, de Arriba F, Cedena MT, Puig N, Oriol A, Paiva B, Bladé J, Lahuerta JJ, San Miguel JF.

Blood Cancer J. 2019 Mar 18;9(4):36. doi: 10.1038/s41408-019-0176-x.

9.

Correction: Early myeloma-related death in elderly patients: development of a clinical prognostic score and evaluation of response sustainability role.

Rodríguez-Otero P, Mateos MV, Martínez-López J, Martín-Calvo N, Hernández MT, Ocio EM, Rosiñol L, Martínez R, Teruel AI, Gutiérrez NC, Bargay J, Bengoechea E, González Y, de Oteyza JP, Gironella M, Encinas C, Martín J, Cabrera C, Palomera L, de Arriba F, Cedena MT, Paiva B, Puig N, Oriol A, Bladé J, Lahuerta JJ, Miguel JFS.

Leukemia. 2019 Apr;33(4):1056. doi: 10.1038/s41375-019-0408-x.

PMID:
30846864
10.

Pomalidomide-dexamethasone for treatment of soft-tissue plasmacytomas in patients with relapsed / refractory multiple myeloma.

Jiménez-Segura R, Granell M, Gironella M, Abella E, García-Guiñón A, Oriol A, Cabezudo E, Clapés V, Soler JA, Escoda L, López-Pardo J, Fernández de Larrea C, Cibeira MT, Tovar N, Isola I, Bladé J, Rosiñol L; GEMMAC (Grup per l l'estudi del mieloma mútiple i l'amiloïdosi de Catalunya).

Eur J Haematol. 2019 May;102(5):389-394. doi: 10.1111/ejh.13217. Epub 2019 Feb 25.

PMID:
30719772
11.

Improving security of autologous hematopoietic stem cell transplant in patients with light-chain amyloidosis.

Gutiérrez-García G, Cibeira MT, Rovira M, Fernández de Larrea C, Tovar N, Rodríguez-Lobato LG, Rosiñol L, Marín P, Solano-Vega J, Suárez-Lledó M, Bataller A, Solano MT, de Llobet N, Domenech A, Borràs N, Lozano M, Cid J, Martínez C, Urbano-Ispizua Á, Esteve J, Carreras E, Fernández-Avilés F, Bladé J.

Bone Marrow Transplant. 2019 Aug;54(8):1295-1303. doi: 10.1038/s41409-019-0447-y. Epub 2019 Jan 21.

PMID:
30664727
12.

Successful treatment with ribavirine for chronic hepatitis E in chronic lymphocytic leukemia treated with Ibrutinib.

Boudin L, Patient M, Tsitsi Nding Tsogou P, Roméo E, Bladé JS, de Jauréguiberry JP.

Bull Cancer. 2019 Jan;106(1):84-85. doi: 10.1016/j.bulcan.2018.11.011. Epub 2018 Dec 19. No abstract available.

PMID:
30579570
13.

M-protein-related disorders: MGCS.

Bladé J, Cibeira MT.

Blood. 2018 Oct 4;132(14):1464-1465. doi: 10.1182/blood-2018-07-865642. No abstract available.

PMID:
30287466
14.

Prognostic utility of serum free light chain ratios and heavy-light chain ratios in multiple myeloma in three PETHEMA/GEM phase III clinical trials.

Lopez-Anglada L, Cueto-Felgueroso C, Rosiñol L, Oriol A, Teruel AI, Lopez de la Guia A, Bengoechea E, Palomera L, de Arriba F, Hernandez JM, Granell M, Peñalver FJ, Garcia-Sanz R, Besalduch J, Gonzalez Y, Martinez RB, Hernandez MT, Gutierrez NC, Puerta P, Valeri A, Paiva B, Blade J, Mateos MV, San Miguel J, Lahuerta JJ, Martinez-Lopez J; GEM (Grupo Español de MM)/PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) Cooperative Study Group.

PLoS One. 2018 Sep 7;13(9):e0203392. doi: 10.1371/journal.pone.0203392. eCollection 2018.

15.

Outcome of Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis Associated With Deletion of 17p.

Wong SW, Hegenbart U, Palladini G, Shah GL, Landau HJ, Warner M, Toskic D, Jaccard A, Hansen T, Bladé J, Cibeira MT, Kastritis E, Dispenzieri A, Wechalekar A, Varga C, Schönland SO, Comenzo RL.

Clin Lymphoma Myeloma Leuk. 2018 Nov;18(11):e493-e499. doi: 10.1016/j.clml.2018.07.292. Epub 2018 Jul 25.

16.

Maintenance Treatment and Survival in Patients With Myeloma: A Systematic Review and Network Meta-analysis.

Gay F, Jackson G, Rosiñol L, Holstein SA, Moreau P, Spada S, Davies F, Lahuerta JJ, Leleu X, Bringhen S, Evangelista A, Hulin C, Panzani U, Cairns DA, Di Raimondo F, Macro M, Liberati AM, Pawlyn C, Offidani M, Spencer A, Hájek R, Terpos E, Morgan GJ, Bladé J, Sonneveld P, San-Miguel J, McCarthy PL, Ludwig H, Boccadoro M, Mateos MV, Attal M.

JAMA Oncol. 2018 Oct 1;4(10):1389-1397. doi: 10.1001/jamaoncol.2018.2961.

17.

Mutational screening of newly diagnosed multiple myeloma patients by deep targeted sequencing.

Ruiz-Heredia Y, Sánchez-Vega B, Onecha E, Barrio S, Alonso R, Martínez-Ávila JC, Cuenca I, Agirre X, Braggio E, Hernández MT, Martínez R, Rosiñol L, Gutierrez N, Martin-Ramos M, Ocio EM, Echeveste MA, de Oteyza JP, Oriol A, Bargay J, Gironella M, Ayala R, Bladé J, Mateos MV, Kortum KM, Stewart K, García-Sanz R, Miguel JS, Lahuerta JJ, Martinez-Lopez J.

Haematologica. 2018 Nov;103(11):e544-e548. doi: 10.3324/haematol.2018.188839. Epub 2018 Jun 28. No abstract available.

18.

A phase I/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma.

San-Miguel JF, Echeveste Gutierrez MA, Špicka I, Mateos MV, Song K, Craig MD, Bladé J, Hájek R, Chen C, Di Bacco A, Estevam J, Gupta N, Byrne C, Lu V, van de Velde H, Lonial S.

Haematologica. 2018 Sep;103(9):1518-1526. doi: 10.3324/haematol.2017.185991. Epub 2018 Jun 28.

19.

[A long-term response to eribulin].

Patient M, Tsogou PTN, Roméo E, Bladé JS, de Jauréguiberry JP, Boudin L.

Bull Cancer. 2018 Jul - Aug;105(7-8):636-638. doi: 10.1016/j.bulcan.2018.05.002. Epub 2018 Jun 14. French. No abstract available.

PMID:
29910045
20.

Treatment of Relapsed Myeloma in a Patient With Renal Insufficiency.

Bladé J, Rosiñol L, Cibeira MT, Fernández de Larrea C.

J Clin Oncol. 2018 Jul 10;36(20):2012-2016. doi: 10.1200/JCO.2017.77.6419. Epub 2018 May 31.

PMID:
29851545
21.

The pattern of the M-protein in smoldering myeloma over the time: an evolving risk factor.

Fernández de Larrea C, Isola I, Pereira A, Cibeira MT, Bladé J, Rosiñol L.

Leukemia. 2018 Sep;32(9):2082-2094. doi: 10.1038/s41375-018-0156-3. Epub 2018 May 23. No abstract available.

PMID:
29795240
22.

Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network.

Ludwig H, Delforge M, Facon T, Einsele H, Gay F, Moreau P, Avet-Loiseau H, Boccadoro M, Hajek R, Mohty M, Cavo M, Dimopoulos MA, San-Miguel JF, Terpos E, Zweegman S, Garderet L, Mateos MV, Cook G, Leleu X, Goldschmidt H, Jackson G, Kaiser M, Weisel K, van de Donk NWCJ, Waage A, Beksac M, Mellqvist UH, Engelhardt M, Caers J, Driessen C, Bladé J, Sonneveld P.

Leukemia. 2018 Jul;32(7):1542-1560. doi: 10.1038/s41375-018-0040-1. Epub 2018 May 2. Review.

23.

Innovative strategies minimize engraftment syndrome in multiple myeloma patients with novel induction therapy following autologous hematopoietic stem cell transplantation.

Gutiérrez-García G, Rovira M, Magnano L, Rosiñol L, Bataller A, Suárez-Lledó M, Cibeira MT, de Larrea CF, Garrote M, Jorge S, Moreno A, Rodríguez-Lobato LG, Carreras E, Díaz-Ricart M, Palomo M, Martínez C, Urbano-Ispizua A, Bladé J, Fernández-Avilés F.

Bone Marrow Transplant. 2018 Dec;53(12):1541-1547. doi: 10.1038/s41409-018-0189-2. Epub 2018 Apr 29.

PMID:
29706650
24.

Efficacy of ibrutinib as first-line treatment of tumoral Bing-Neel syndrome.

Boudin L, Patient M, Roméo E, Bladé JS, de Jauréguiberry JP.

Leuk Lymphoma. 2018 Nov;59(11):2746-2748. doi: 10.1080/10428194.2018.1441409. Epub 2018 Mar 23. No abstract available.

PMID:
29569974
25.

A novel nano-immunoassay method for quantification of proteins from CD138-purified myeloma cells: biological and clinical utility.

Misiewicz-Krzeminska I, Corchete LA, Rojas EA, Martínez-López J, García-Sanz R, Oriol A, Bladé J, Lahuerta JJ, Miguel JS, Mateos MV, Gutiérrez NC.

Haematologica. 2018 May;103(5):880-889. doi: 10.3324/haematol.2017.181628. Epub 2018 Mar 15.

26.

Loss of the Immune Checkpoint CD85j/LILRB1 on Malignant Plasma Cells Contributes to Immune Escape in Multiple Myeloma.

Lozano E, Díaz T, Mena MP, Suñe G, Calvo X, Calderón M, Pérez-Amill L, Rodríguez V, Pérez-Galán P, Roué G, Cibeira MT, Rosiñol L, Isola I, Rodríguez-Lobato LG, Martin-Antonio B, Bladé J, Fernández de Larrea C.

J Immunol. 2018 Apr 15;200(8):2581-2591. doi: 10.4049/jimmunol.1701622. Epub 2018 Mar 12.

27.

Early myeloma-related death in elderly patients: development of a clinical prognostic score and evaluation of response sustainability role.

Rodríguez-Otero P, Mateos MV, Martínez-López J, Martín-Calvo N, Hernández MT, Ocio EM, Rosiñol L, Martínez R, Teruel AI, Gutiérrez NC, Bargay J, Bengoechea E, González Y, de Oteyza JP, Gironella M, Encinas C, Martín J, Cabrera C, Palomera L, de Arriba F, Cedena MT, Paiva B, Puig N, Oriol A, Bladé J, Lahuerta JJ, San Miguel JF.

Leukemia. 2018 Nov;32(11):2427-2434. doi: 10.1038/s41375-018-0072-6. Epub 2018 Feb 23. Erratum in: Leukemia. 2019 Apr;33(4):1056.

PMID:
29515235
28.

Bone marrow plasma cell infiltration in light chain amyloidosis: impact on organ involvement and outcome.

Tovar N, Rodríguez-Lobato LG, Cibeira MT, Magnano L, Isola I, Rosiñol L, Bladé J, Fernández de Larrea C.

Amyloid. 2018 Jun;25(2):79-85. doi: 10.1080/13506129.2018.1443439. Epub 2018 Feb 26.

PMID:
29482381
29.

Defining a set of standardised outcome measures for newly diagnosed patients with multiple myeloma using the Delphi consensus method: the IMPORTA project.

Blade J, Calleja MÁ, Lahuerta JJ, Poveda JL, de Paz HD, Lizán L.

BMJ Open. 2018 Feb 22;8(2):e018850. doi: 10.1136/bmjopen-2017-018850.

30.

Evolving M-protein pattern in patients with smoldering multiple myeloma: impact on early progression.

Fernández de Larrea C, Isola I, Pereira A, Cibeira MT, Magnano L, Tovar N, Rodríguez-Lobato LG, Calvo X, Aróstegui JI, Díaz T, Lozano E, Rozman M, Yagüe J, Bladé J, Rosiñol L.

Leukemia. 2018 Jun;32(6):1427-1434. doi: 10.1038/s41375-018-0013-4. Epub 2018 Feb 2.

PMID:
29463830
31.

Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel.

Caers J, Paiva B, Zamagni E, Leleu X, Bladé J, Kristinsson SY, Touzeau C, Abildgaard N, Terpos E, Heusschen R, Ocio E, Delforge M, Sezer O, Beksac M, Ludwig H, Merlini G, Moreau P, Zweegman S, Engelhardt M, Rosiñol L.

J Hematol Oncol. 2018 Jan 16;11(1):10. doi: 10.1186/s13045-017-0549-1. Review.

32.

Testicular plasmacytoma: unique location or circumstantial presentation?

Muchtar E, Bladé J, Gertz MA.

Leuk Lymphoma. 2018 Aug;59(8):1769-1771. doi: 10.1080/10428194.2017.1421763. Epub 2018 Jan 9. No abstract available.

PMID:
29316841
33.

[Acute liver failure secondary to diffuse liver infiltration].

Matray C, Roméo E, Bladé JS, de Jauréguiberry JP, Boudin L.

Presse Med. 2018 Jan;47(1):100-101. doi: 10.1016/j.lpm.2017.09.022. Epub 2017 Dec 20. French. No abstract available.

PMID:
29275024
34.

Prognostic value of antigen expression in multiple myeloma: a PETHEMA/GEM study on 1265 patients enrolled in four consecutive clinical trials.

Arana P, Paiva B, Cedena MT, Puig N, Cordon L, Vidriales MB, Gutierrez NC, Chiodi F, Burgos L, Anglada LL, Martinez-Lopez J, Hernandez MT, Teruel AI, Gironella M, Echeveste MA, Rosiñol L, Martinez R, Oriol A, De la Rubia J, Orfao A, Blade J, Lahuerta JJ, Mateos MV, San Miguel JF.

Leukemia. 2018 Apr;32(4):971-978. doi: 10.1038/leu.2017.320. Epub 2017 Nov 3.

35.

Prognostic impact of immunoparesis at diagnosis and after treatment onset in patients with light-chain amyloidosis.

Rodríguez-Lobato LG, Fernández de Larrea C, Cibeira MT, Tovar N, Isola I, Aróstegui JI, Rosiñol L, Díaz T, Lozano E, Yagüe J, Bladé J.

Amyloid. 2017 Dec;24(4):245-252. doi: 10.1080/13506129.2017.1390451. Epub 2017 Oct 20.

PMID:
29052436
36.

[Lenalidomide desensitization in a patient with 5q- syndrome].

Boudin L, Patient M, Roméo E, Bladé JS, de Jauréguiberry JP.

Bull Cancer. 2017 Sep;104(9):814-816. doi: 10.1016/j.bulcan.2017.06.014. Epub 2017 Aug 1. French. No abstract available.

PMID:
28778340
37.

The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in in vitro and in vivo models of multiple myeloma by blockade of Ikaros and MYC signaling.

Díaz T, Rodríguez V, Lozano E, Mena MP, Calderón M, Rosiñol L, Martínez A, Tovar N, Pérez-Galán P, Bladé J, Roué G, de Larrea CF.

Haematologica. 2017 Oct;102(10):1776-1784. doi: 10.3324/haematol.2017.164632. Epub 2017 Jul 27.

38.

Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials.

Lahuerta JJ, Paiva B, Vidriales MB, Cordón L, Cedena MT, Puig N, Martinez-Lopez J, Rosiñol L, Gutierrez NC, Martín-Ramos ML, Oriol A, Teruel AI, Echeveste MA, de Paz R, de Arriba F, Hernandez MT, Palomera L, Martinez R, Martin A, Alegre A, De la Rubia J, Orfao A, Mateos MV, Blade J, San-Miguel JF; GEM (Grupo Español de Mieloma)/PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) Cooperative Study Group.

J Clin Oncol. 2017 Sep 1;35(25):2900-2910. doi: 10.1200/JCO.2016.69.2517. Epub 2017 May 12.

39.

Impact of Autologous Stem Cell Transplantation on the Incidence and Outcome of Oligoclonal Bands in Patients with Light-Chain Amyloidosis.

Rodríguez-Lobato LG, Fernández de Larrea C, Cibeira MT, Tovar N, Aróstegui JI, Rosiñol L, Díaz T, Lozano E, Elena M, Yagüe J, Bladé J.

Biol Blood Marrow Transplant. 2017 Aug;23(8):1269-1275. doi: 10.1016/j.bbmt.2017.04.012. Epub 2017 Apr 18.

40.

Renal outcomes of autologous stem cell transplantation among patients with light-chain amyloidosis: a single centre Spanish experience.

Azorín SE, Cibeira MT, Solé M, Fernández de Larrea C, Rosiñol L, Rovira M, Campistol JM, Bladé J.

Amyloid. 2017 Mar;24(sup1):70-71. doi: 10.1080/13506129.2017.1293646. No abstract available.

PMID:
28434321
41.

Management of smoldering myeloma: Recommendations of the Spanish Myeloma Group.

Mateos MV, Bladé J, Lahuerta JJ, San-Miguel J.

Med Clin (Barc). 2017 Jun 7;148(11):517-523. doi: 10.1016/j.medcli.2017.02.012. Epub 2017 Mar 22. English, Spanish. No abstract available.

PMID:
28341370
42.

Prognostic impact of circulating plasma cells in patients with multiple myeloma: implications for plasma cell leukemia definition.

Granell M, Calvo X, Garcia-Guiñón A, Escoda L, Abella E, Martínez CM, Teixidó M, Gimenez MT, Senín A, Sanz P, Campoy D, Vicent A, Arenillas L, Rosiñol L, Sierra J, Bladé J, de Larrea CF; GEMMAC (Grup per l’estudi del mieloma i l’amiloïdosi de Catalunya).

Haematologica. 2017 Jun;102(6):1099-1104. doi: 10.3324/haematol.2016.158303. Epub 2017 Mar 2.

43.

Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myeloma.

Martinez-Lopez J, Sanchez-Vega B, Barrio S, Cuenca I, Ruiz-Heredia Y, Alonso R, Rapado I, Marin C, Cedena MT, Paiva B, Puig N, Mateos MV, Ayala R, Hernández MT, Jimenez C, Rosiñol L, Martínez R, Teruel AI, Gutiérrez N, Martin-Ramos ML, Oriol A, Bargay J, Bladé J, San-Miguel J, Garcia-Sanz R, Lahuerta JJ.

Leukemia. 2017 Jun;31(6):1446-1449. doi: 10.1038/leu.2017.58. Epub 2017 Feb 17. No abstract available.

44.

Bortezomib and thalidomide maintenance after stem cell transplantation for multiple myeloma: a PETHEMA/GEM trial.

Rosiñol L, Oriol A, Teruel AI, de la Guía AL, Blanchard M, de la Rubia J, Granell M, Sampol M, Palomera L, González Y, Etxebeste M, Martínez-Martínez R, Hernández MT, de Arriba F, Alegre A, Cibeira M, Mateos M, Martínez-López J, Lahuerta JJ, San Miguel J, Bladé J.

Leukemia. 2017 Sep;31(9):1922-1927. doi: 10.1038/leu.2017.35. Epub 2017 Jan 23.

PMID:
28111466
45.

[Acquired, non-amyloid related factor X deficiency: A first case associated with atypical chronic lymphocytic leukemia and literature review].

Boudin L, Patient M, Roméo E, Bladé JS, Gisserot O, de Jauréguiberry JP.

Rev Med Interne. 2017 Jul;38(7):478-481. doi: 10.1016/j.revmed.2016.12.003. Epub 2017 Jan 19. Review. French.

PMID:
28110969
46.

Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma.

Flores-Montero J, Sanoja-Flores L, Paiva B, Puig N, García-Sánchez O, Böttcher S, van der Velden VHJ, Pérez-Morán JJ, Vidriales MB, García-Sanz R, Jimenez C, González M, Martínez-López J, Corral-Mateos A, Grigore GE, Fluxá R, Pontes R, Caetano J, Sedek L, Del Cañizo MC, Bladé J, Lahuerta JJ, Aguilar C, Bárez A, García-Mateo A, Labrador J, Leoz P, Aguilera-Sanz C, San-Miguel J, Mateos MV, Durie B, van Dongen JJM, Orfao A.

Leukemia. 2017 Oct;31(10):2094-2103. doi: 10.1038/leu.2017.29. Epub 2017 Jan 20.

47.

[Hyperleucocytosis with acute uric acid nephropathy in a patient with hepatocellular carcinoma].

Boudin L, Patient M, Roméo E, Bladé JS, de Jauréguiberry JP.

Presse Med. 2017 Mar;46(2 Pt 1):238-239. doi: 10.1016/j.lpm.2016.11.028. Epub 2017 Jan 10. French. No abstract available.

PMID:
28087209
48.

Absence of spontaneous response improvement beyond day +100 after autologous stem cell transplantation in multiple myeloma.

Fernández de Larrea C, Dávila J, Isola I, Ocio EM, Rosiñol L, García-Sanz R, Cibeira MT, Tovar N, Rovira M, Mateos MV, Miguel JS, Bladé J.

Bone Marrow Transplant. 2017 Apr;52(4):567-569. doi: 10.1038/bmt.2016.299. Epub 2016 Nov 21.

PMID:
27869809
49.

A Next-Generation Sequencing Strategy for Evaluating the Most Common Genetic Abnormalities in Multiple Myeloma.

Jiménez C, Jara-Acevedo M, Corchete LA, Castillo D, Ordóñez GR, Sarasquete ME, Puig N, Martínez-López J, Prieto-Conde MI, García-Álvarez M, Chillón MC, Balanzategui A, Alcoceba M, Oriol A, Rosiñol L, Palomera L, Teruel AI, Lahuerta JJ, Bladé J, Mateos MV, Orfão A, San Miguel JF, González M, Gutiérrez NC, García-Sanz R.

J Mol Diagn. 2017 Jan;19(1):99-106. doi: 10.1016/j.jmoldx.2016.08.004. Epub 2016 Nov 15.

PMID:
27863261
50.

Elotuzumab in combination with thalidomide and low-dose dexamethasone: a phase 2 single-arm safety study in patients with relapsed/refractory multiple myeloma.

Mateos MV, Granell M, Oriol A, Martinez-Lopez J, Blade J, Hernandez MT, Martín J, Gironella M, Lynch M, Bleickardt E, Paliwal P, Singhal A, San-Miguel J.

Br J Haematol. 2016 Nov;175(3):448-456. doi: 10.1111/bjh.14263. Epub 2016 Jul 19.

PMID:
27434748

Supplemental Content

Support Center